Back to Results

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc. is a biotechnology company focused on discovering and developing antiviral therapies for serious and chronic viral diseases. Its research programs use structure-based technologies to target a range of viruses, including influenza, coronaviruses such as SARS-CoV-2 and MERS-CoV, norovirus, respiratory virus infections, and hepatitis C virus. The company’s pipeline includes CC-42344, a PB2 inhibitor in Phase 2a development for pandemic and seasonal influenza A, along with an inhaled version being studied for prophylactic use against influenza infections. Cocrystal is also advancing CDI-988, an oral pan-viral candidate in Phase 1 testing for noroviruses and coronaviruses, and CC-31244, a non-nucleoside HCV inhibitor that has completed Phase 2a trials. In addition, the company has research collaborations with Merck Sharp & Dohme and Kansas State University Research Foundation.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-COCP	$0.71	-40.1% Downside	Overvalued	$9	656.3% Upside	Bargain	Fair	0.0%	November 16, 2026	22.0x	69.5x	22.923 M	22.095 M	5.5%	61.8%	-107.8	80.2%

Smart Snapshot

Stock Overview

A fast read of the company and market metrics currently supported by the latest data.

Company Profile

Sector

Healthcare

Index Membership

Strong Buy

Valuation Snapshot

Fair Value

$0.71

Valuation Gap

-40.1% Downside

Analyst Target

Quality & Risk

Financial Health

Fair

Piotroski Score

-10.06 M

Altman Z-Score

-107.8

Upcoming Events

Next Earnings Date

November 16, 2026

Days to Earnings

Strong Buy

Valuation • Fair Value

Cocrystal Pharma Inc (NASDAQ-COCP) Fair Value by Valuation Model

Review the available estimates for Cocrystal Pharma Inc (NASDAQ-COCP), including Ben Graham Formula Value.

Primary Valuation Read

Fair Value

$0.71

Estimated downside of 40.1% versus the current market price.

Ben Graham Formula Value

Classic Ben Graham valuation formula reference.

Analyst Price Target

Analysts imply upside of 656.3%.

How to read these valuation models

Use the 3 available valuation references for Cocrystal Pharma Inc (NASDAQ-COCP) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cocrystal Pharma Inc (NASDAQ-COCP)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

Strong Sell

Current operating scale indicator.

Revenue Forecast

Neutral

Forward revenue estimate.

EBITDA

Pharmaceuticals

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Cocrystal Pharma Inc (NASDAQ-COCP) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cocrystal Pharma Inc (NASDAQ-COCP)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

-10.06 M

Weak quality score that deserves closer review.

Altman Z-Score

-107.8

Lower score that deserves closer risk review.

FCF / Net Income

80.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cocrystal Pharma Inc (NASDAQ-COCP). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cocrystal Pharma Inc (NASDAQ-COCP)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

Strong Buy

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Cocrystal Pharma Inc (NASDAQ-COCP), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Analyst Outlook

Analyst Consensus for Cocrystal Pharma Inc (NASDAQ-COCP)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Analyst Consensus for Cocrystal Pharma Inc (NASDAQ-COCP)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy

Consolidated analyst recommendation mix

Hold

Based on the available recommendation mix, Cocrystal Pharma Inc (NASDAQ-COCP) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0

Hold 1

Sell 0

FAQ • Fast Investor Answers

Cocrystal Pharma Inc (NASDAQ-COCP) Stock FAQ

Data-supported answers about Cocrystal Pharma Inc (NASDAQ-COCP), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value

$0.71

Estimated downside 40.1%

Valuation Rating

Overvalued

Estimated downside of 40.1%

Analyst Target

Implied upside 656.3%

Financial Health

Fair

Current financial-health read

The current fair value estimate for Cocrystal Pharma Inc (NASDAQ-COCP) is $0.71. This implies an estimated downside of 40.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 40.1% versus the current market price.

The available analyst price target for Cocrystal Pharma Inc (NASDAQ-COCP) is $9. The analyst target implies estimated upside of 656.3%.

The current financial health read for Cocrystal Pharma Inc (NASDAQ-COCP) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cocrystal Pharma Inc (NASDAQ-COCP) is November 16, 2026.

The latest available data indicates no current dividend yield for Cocrystal Pharma Inc (NASDAQ-COCP).

The current market capitalization listed for Cocrystal Pharma Inc is 22.923 M.

The current enterprise value listed for Cocrystal Pharma Inc is 22.095 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cocrystal Pharma Inc is NASDAQ-COCP, and the stock is listed on NASDAQ.

Cocrystal Pharma Inc (NASDAQ-COCP) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Cocrystal Pharma Inc is 5.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cocrystal Pharma Inc is 61.8%. Free float helps investors understand how much of the share base is available for public trading.